- Home
- OBE vs CADL Comparison
OBE vs CADL Comparison
Compare OBE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBE
- CADL
- Stock Information
- Founded
- OBE 1979
- CADL 1999
- Country
- OBE Canada
- CADL United States
- Employees
- OBE N/A
- CADL N/A
- Industry
- OBE Oil & Gas Production
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- OBE Energy
- CADL Health Care
- Exchange
- OBE Nasdaq
- CADL Nasdaq
- Market Cap
- OBE 393.3M
- CADL 339.8M
- IPO Year
- OBE N/A
- CADL 2021
- Fundamental
- Price
- OBE $6.04
- CADL $4.65
- Analyst Decision
- OBE Hold
- CADL Strong Buy
- Analyst Count
- OBE 1
- CADL 7
- Target Price
- OBE $9.00
- CADL $19.43
- AVG Volume (30 Days)
- OBE 339.9K
- CADL 684.9K
- Earning Date
- OBE 10-30-2025
- CADL 11-13-2025
- Dividend Yield
- OBE N/A
- CADL N/A
- EPS Growth
- OBE N/A
- CADL N/A
- EPS
- OBE N/A
- CADL N/A
- Revenue
- OBE $441,312,666.00
- CADL N/A
- Revenue This Year
- OBE N/A
- CADL N/A
- Revenue Next Year
- OBE N/A
- CADL N/A
- P/E Ratio
- OBE N/A
- CADL N/A
- Revenue Growth
- OBE N/A
- CADL N/A
- 52 Week Low
- OBE $3.88
- CADL $4.25
- 52 Week High
- OBE $7.07
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- OBE 48.18
- CADL 40.80
- Support Level
- OBE $5.90
- CADL $4.35
- Resistance Level
- OBE $6.25
- CADL $4.68
- Average True Range (ATR)
- OBE 0.26
- CADL 0.28
- MACD
- OBE 0.00
- CADL -0.01
- Stochastic Oscillator
- OBE 42.54
- CADL 27.84
About OBE Obsidian Energy Ltd.
Obsidian Energy Ltd is an intermediate-sized oil and gas producer with strategic assets in Alberta. It operates in a single reporting segment that is exploration, development, and holding an interest in oil and natural gas properties and related production infrastructure in the Western Canada Sedimentary Basin. The company generates the majority of the revenue from the Crude oil sale.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.